Ask A L, Fagervall I, Jonze M, Kelder D, Nygren R, Ross S B
Biochem Pharmacol. 1984 Sep 15;33(18):2839-47. doi: 10.1016/0006-2952(84)90205-3.
The inhibitory effect on monoamine oxidase (MAO) of the reversible MAO-A inhibitor (+)-4-dimethylamino-2,alpha-dimethylphenethylamine [amiflamine, FLA 336(+)] was evaluated in the rat after acute and repeated (twice daily for two weeks) oral treatment. MAO activity was measured ex vivo in slices from the hypothalamus and the duodenum for both MAO-A and MAO-B. Amiflamine selectively inhibited the A form of MAO after repeated as well as after acute treatment (ED50 approximately 7 mumoles/kg both acute and repeated). In the brain slices this inhibition corresponded to a decrease in the concentration of 5-hydroxyindoleacetic acid (5-HIAA) and to an increase in the concentration of 5-HT in the hypothalamus, the hippocampus and the striatum. The concentration of 3,4-dihydroxyphenylacetic acid (DOPAC) was decreased in the striatum to the same extent as the decrease in the 5-HIAA concentrations. The effect on the homovanillic acid (HVA) concentration was somewhat weaker as was the increase in the concentration of dopamine. No essential difference was found after acute and chronic treatment on the amine and metabolite levels. The MAO activity returned to normal 24 hours after final dosing. A large difference between the neuronal and the extraneuronal protection against the phenelzine-induced irreversible MAO inhibition in the hypothalamus was found after both acute and repeated treatment. The ED50 of the protection within the serotonergic neurons was 1.3 mumoles/kg p.o. (acute) and 0.75 mumoles/kg p.o. (repeated). Amiflamine was 3 times less potent within noradrenergic neurons than within serotonergic neurons. A brain to plasma ratio of about 20:1 was found for amiflamine and its metabolites. The plasma and the brain concentrations of the N-demethylated metabolite [FLA 788(+)] exceeded that of amiflamine after a single dose, whereas the N,N-demethylated [FLA 668(+)] was found in low concentrations. The effect on MAO-A correlated significantly with the plasma and the brain concentration of FLA 788(+).
在大鼠经急性和重复(每日两次,持续两周)口服治疗后,评估了可逆性单胺氧化酶-A抑制剂(+)-4-二甲基氨基-2,α-二甲基苯乙胺[阿米氟明,FLA 336(+)]对单胺氧化酶(MAO)的抑制作用。对下丘脑和十二指肠切片中的MAO-A和MAO-B进行体外MAO活性测定。无论是重复给药还是急性给药后,阿米氟明均选择性抑制MAO的A形式(急性和重复给药的半数有效量均约为7微摩尔/千克)。在脑切片中,这种抑制作用表现为下丘脑、海马体和纹状体中5-羟吲哚乙酸(5-HIAA)浓度降低,5-羟色胺(5-HT)浓度升高。纹状体中3,4-二羟基苯乙酸(DOPAC)浓度的降低程度与5-HIAA浓度的降低程度相同。对高香草酸(HVA)浓度的影响较弱,多巴胺浓度的升高也较弱。急性和慢性治疗后,胺和代谢物水平未发现本质差异。末次给药24小时后,MAO活性恢复正常。急性和重复治疗后,均发现下丘脑神经元和非神经元对苯乙肼诱导的不可逆MAO抑制的保护作用存在很大差异。5-羟色胺能神经元内保护作用的半数有效量为口服1.3微摩尔/千克(急性)和0.75微摩尔/千克(重复)。阿米氟明在去甲肾上腺素能神经元中的效力比在5-羟色胺能神经元中低3倍。发现阿米氟明及其代谢物的脑-血浆比约为20:1。单次给药后,N-去甲基代谢物[FLA 788(+)]的血浆和脑浓度超过了阿米氟明,而N,N-去甲基代谢物[FLA 668(+)]的浓度较低。对MAO-A的作用与FLA 788(+)的血浆和脑浓度显著相关。